Should Antiarrhythmic Drugs Be Administered After First Appropriate ICD Shock, and If So, Which Ones?

  • G. Abali
  • K. Aytemir
  • A. Oto
Conference paper


Implantable cardioverter defibrillator (ICD) devices have been used for many years to prevent sudden cardiac death. Rapidly evolving ICD technology has widened the indications and clinical applications of these devices. Despite the technological advances, however, patients with ICDs are still at risk of sudden arrhythmic cardiac death. Furthermore, ventricular arrhythmias that require shock therapy, and inappropriate shocks triggered by supraventricular arrhythmias, adversely affect the quality of life of patients with implanted ICDs. However, many patients with ICDs have been discharged with no antiarrhythmic drug prescription. The addition of adjuvant antiarrhythmic drug treatment to ICD therapy is frequently required after the first shock therapy, to improve the quality of life of these patients.


Implantable Cardioverter Defibrillator Antiarrhythmic Drug Brugada Syndrome Shock Therapy Implantable Cardioverter Defibrillator Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Levine JH, Mellits D, Baumgartner RA et al (1991) Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter defibrilla-tors. Circulation 84:558–566PubMedCrossRefGoogle Scholar
  2. 2.
    Ceremuzynski L (1993) Secondary prevention after myocardial infarction with class III antiarrhythmic drugs. Am J Cardiol 72:82FPubMedCrossRefGoogle Scholar
  3. 3.
    Julian DG, Camm AJ, Frangin G et al (1997) Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recurrent myocardial infarction: EMIAT. Lancet 349:667PubMedCrossRefGoogle Scholar
  4. 4.
    Dorian P (1998) Interactions between implantable devices and pharmacological agents. Card Electrophysiol Rev 2:151–153CrossRefGoogle Scholar
  5. 5.
    Epstein AE, Ellenbogen KA, Kirk KA et al (1992) Clinical characteristics and outcome of patients with high defibrillation thresholds. A multicenter study. Circulation 86:1206–1216PubMedCrossRefGoogle Scholar
  6. 6.
    Kühlkamp V, Mewis C, Suchalla R et al (1999) Effects of amiodarone and sotalol on defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. Int J Cardiol 69:271–279PubMedCrossRefGoogle Scholar
  7. 7.
    Dolak GL for the CASCADE investigators (1994) Clinical predictors of ICD shocks. Am J Cardiol 73:237–241CrossRefGoogle Scholar
  8. 8.
    Kettering K, Mewis C, Dörnberger V et al (2002) Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. J Pacing Electrophysiol 25:1571–1576CrossRefGoogle Scholar
  9. 9.
    Seidl K, Hauer B, Schwick N et al (1998) Comparision of metoprolol and sotalol in preventing ventricular tachyarrhythmias after implntation of ICD. Am J Cardiol 82:744–748PubMedCrossRefGoogle Scholar
  10. 10.
    Dorian P, Newman D, Sheahan R et al (1996) D-sotalol decreases defibrillation energy requirements in humans. A novel indication for drug therapy. J Cardiovasc Electrophysiol 7:952–961PubMedCrossRefGoogle Scholar
  11. 11.
    Pacifico A, Hohnloser SH, Williams JH et al ( 1999) Prevention of implantable defibrillator shock by treatment with sotalol. N Engl J Med 340:1855–1862PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • G. Abali
    • 1
  • K. Aytemir
    • 1
  • A. Oto
    • 1
  1. 1.Department of CardiologyHacettepe UniversityAnkaraTurkey

Personalised recommendations